Advertisement
Advertisement

JANX

JANX logo

Janux Therapeutics Inc

55.12
USD
-4.49
-7.53%
Dec 18, 15:59 UTC -5
Closed
...

Janux Therapeutics Inc Profile

About

Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.

Info & Links

CEO

David Campbell

Headquarters

10955 Vista Sorrento Parkway, Suite 200
San Diego, CA 92130, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

24

Employees

64

Janux Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

2.89B

Enterprise Value

2.87B

Enterprise Value/EBITDA(ttm)

-30.62

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

245.78

Price to Book(mrq)

4.86

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-463.91%

Profit Margin(ttm)

-2028.81%

Return on Equity(ttm)

-10.47%

Return on Invested Capital(ttm)

-10.85%

Return on Assets(ttm)

-9.86%

Income Statement

Revenue(ttm)

13.05M

Revenue Per Share(ttm)

0.25

Gross Profit(ttm)

13.05M

EBITDA(ttm)3

-93.60M

Net Income Available to Common(ttm)

-60.54M

Diluted EPS(ttm)

-1.17

Share Statistics

Beta (5Y Monthly)

3.29

52-Week Change

497.83%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

52.48M

Dividend Yield

0.00%

Float4

37.05M

% Held by Insiders

29.40%

% Held by Institutions

75.39%

Balance Sheet

Total Cash(mrq)

658.03M

Total Cash Per Share(mrq)

12.54

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

38.80%

Quick Ratio(mrq)

38.80%

Book Value Per Share(mrq)

12.54

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.50

Free Cash Flow(ytd)

-27.41M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement